Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.685 +0.065 (+4.01%)
Streaming Delayed Price Updated: 1:04 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences, Inc. (NASDAQ:CRBU) Long Term Investor Alert: Investigation over Possible Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 05/22/2023 -- Certain directors of Caribou Biosciences, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
News headline image
Caribou Biosciences: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
HC Wainwright & Co. Maintains Buy Rating for Caribou Biosciences: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Caribou Biosciences, Inc. (CRBU) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
CARIBOU DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CRBU FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important April 11 Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
NASDAQ:CRBU Investor Alert: Deadline on April 11, 2023 in Lawsuit Against Caribou Biosciences, Inc. Coming Up ↗
San Diego, CA -- (SBWIRE) -- 04/05/2023 -- The Shareholders Foundation announced that a deadline is coming up on April 11, 2023 in the lawsuit filed for certain investors of Caribou Biosciences, Inc.... 
Via SBWire
News headline image
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PLDT, Global Payments, Caribou, and Inspirato and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Caribou Biosciences, Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Atlassian, PLDT, Global Payments, and Caribou and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
WHY: New York, NY - (NewMediaWire) - March 22, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant... 
Via NewMediaWire
Topics Lawsuit
News headline image
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Global Payments, Caribou, Inspirato, and Kornit and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're starting the final day of the week with a breakdown of the biggest pre-market stock movers worth watching on Friday! 
Via InvestorPlace
News headline image
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.